[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631358":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":27,"locations":10,"responsibleParty":33,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":10,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"60 patients diagnosed with B-cell lymphoproliferative disorders (B LPDs).",null,"B-cell lymphoproliferative disorders (B LPDs), including chronic B-cell neoplasms diagnosed by flow cytometry",{"label":13,"type":10,"description":14,"interventionNames":10},"60 patients diagnosed with B-cell acute lymphoblastic leukemia\u002Flymphoma.","B-cell acute lymphoblastic leukemia\u002Flymphoma diagnosed by flow cytometry",{"label":16,"type":10,"description":17,"interventionNames":10},"(control group): 60 apparently healthy individuals","will be included as a control group for comparison",[19,22,25],{"name":20,"affiliation":5,"role":21},"Hesham Abdel-Raheem Abdel-Baset, Professor","STUDY_DIRECTOR",{"name":23,"affiliation":5,"role":24},"Al Shaimaa Mokhtar Selim","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":5,"role":24},"Zeinab Albadry Zahran",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Amira Saber","CONTACT","01063954423","amirasaberh@aun.edu.eg",{"type":24,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Amira Saber Hamed Ahmed","Dr","100631358","immunophenotypic-evaluation-of-cd305-and-cd85d-in-b-cell-lymphoid-neoplasms-100631358",false,"NCT07499635","Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms","Immunophenotypic Evaluation of Inhibitory Immune Receptors CD305 and CD85d in B-Cell Lymphoid Neoplasms","Inclusion Criteria:\n\n* \\- Newly diagnosed cases of B-cell acute lymphoblastic leukemia\u002Flymphoma or B CLPDs according to the WHO classification and established by morphology, immunophenotyping, and, if available, cytogenetic\u002Fmolecular findings.\n\nExclusion Criteria:\n\n* Patients diagnosed with hematologic malignancies other than B-cell acute lymphoblastic leukemia\u002Flymphoma or B CLPDs.\n* Patients who have received prior therapy, including chemotherapy or immunomodulatory treatment.\n* Patients refused to sign informed consent.",true,"ALL",{"count":46,"type":47},180,"ESTIMATED","OBSERVATIONAL","Inhibitory immune receptors, including CD85d and CD305 (LAIR-1), act as immune checkpoint-like molecules. They contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit SH2-domain phosphatases (e.g., SHP-1), which suppress cellular activation (7,8).\n\nCD85d is predominantly expressed in myeloid cells, including monocytes, macrophages, dendritic cells, and granulocytes. It is also differentially expressed on NK, T, B cells, and neutrophils. It is expressed at high levels in tumor cells, facilitating immune escape by promoting immune suppression, allowing for tumor evasion (9).\n\nCD85d is widely expressed across AML, so it is a top candidate, due to its traditional association with myeloid phenotypes and limited expression in normal haematopoiesis (10). It was reported to be expressed in B cells of CLL patients in contrast to normal B cells. Its expression in CLL patients denotes a distinctive feature, which may be acquired during malignant transformation (8). Therefore, CD85d may have significant prognostic, mechanistic, and therapeutic roles in hematologic malignancies (11).\n\nAs a novel biomarker in solid malignant tumors to predict the prognosis of patients, upregulation of CD85d in tumors is associated with worse tumor phenotypes. Targeting CD85d may be an effective tool for targeted cancer therapy (12).\n\nConcerning CD305, it has been reported in about 60% of CLL patients and may be used as an effective prognostic marker to predict TTFT in CLL patients (13).\n\nDespite their potential clinical significance, the expression patterns of CD85d and CD305 across B-cell lymphoid neoplasms subtypes remain incompletely identified. Illustrating their role may help to determine TTFT, prognosis, therapeutic targeting, and refinement of B-cell neoplasms classification in line with WHO-HAEM5 standards.",[51],"B Cell Malignancies",[53],"CD85d, CD305, B-Cell Lymphoid Neoplasms","NOT_YET_RECRUITING","2026-03-24",{"date":57,"type":58},"2026-03-30","ACTUAL",{"date":60,"type":47},"2026-09-06",{"date":62,"type":47},"2029-03",{"name":5,"class":6}]